Agenus achieved net income in Q3 2025 primarily due to a $100.9 million gain from MiNK deconsolidation, despite an operating loss. Revenue grew modestly, supported by licensing and milestone payments, and the company advanced its clinical pipeline, including the initiation of the BATTMAN Phase 3 trial.

Revenue for Q2 2025 was $25.7M, mainly driven by non-cash royalty income. The company posted a net loss of $30.0M, or $1.00 per share, and used $20.2M in cash for operations. Cash and cash equivalents totaled $9.5M at quarter-end, with an additional $5.2M raised post-quarter and $91.0M expected in Q3 from the Zydus collaboration.

Agenus delivered $24.1 million in revenue during Q1 2025, driven primarily by non-cash royalty revenue, and reduced its net loss to $26.4 million. The company emphasized progress in its BOT/BAL immunotherapy programs and improved financial efficiency with reduced cash burn.

Agenus reported Q4 2024 revenue of $26.8 million but incurred a net loss of $46.8 million. The company continued its cost-cutting strategy, reducing its operational burn rate and monetizing non-core assets. Significant progress was made in its BOT/BAL program, with external clinical trials validating its potential. The company also ended the year with $40.4 million in cash and cash equivalents.

Agenus reported revenue of $25.1 million and a net loss of $67.2 million for Q3 2024. The company is focused on advancing BOT/BAL, strategic initiatives including asset monetization and operational efficiencies to strengthen its financial position.

Agenus reported revenue of $23.5 million for the second quarter of 2024 and a net loss of $54.8 million. The company's cash balance was $93.7 million at the end of the quarter. Agenus is focused on advancing its BOT/BAL program and is in discussions with potential partners.

Agenus announced a $100 million royalty financing agreement with Ligand to support BOT/BAL development and launch readiness. The company reported positive clinical results from Phase 1 and Phase 2 studies of BOT/BAL in metastatic relapsed/refractory colorectal cancer. Agenus successfully reduced its cash burn rate and regained compliance with Nasdaq listing.

Agenus reported a net loss of $64.5 million for Q3 2023, with revenue of $24.3 million. The company is focusing on the development of botensilimab and plans to submit a BLA to the FDA for MSS CRC in mid-2024. Agenus believes it is sufficiently funded through the end of 2024 with a cash, cash equivalent, and short-term investment balance of $106.3 million.

Agenus reported Q2 2023 results, highlighting the promising clinical activity of botensilimab, particularly in colorectal cancer, and the FDA's Fast Track designation for the botensilimab/balstilimab combination. The company is advancing its clinical pipeline and preparing for a regulatory submission for botensilimab/balstilimab in colorectal cancer. The company ended the quarter with $157.6 million in cash, cash equivalents and short-term investments, and raised $20.3 million through sales of common stock since the end of Q2 2023. Revenue for the quarter was $25.3 million, and the net loss was $73.4 million.

Agenus Inc. announced its financial results for the quarter ended March 31, 2023.

Agenus reported revenue of $28 million and a net loss of $74 million for the fourth quarter of 2022. The company ended the year with a cash, cash equivalent, and short-term investment balance of $193 million.

Agenus reported revenue of $22.8 million and a net loss of $56.7 million, or $0.19 per share, for the third quarter ended September 30, 2022. The company ended the quarter with $218.2 million in cash, cash equivalents, and short-term investments.

Agenus reported a revenue of $21 million for the second quarter ended June 30, 2022, representing an increase of $10 million from the same period in 2021. The net loss for the quarter was $49 million or $0.17 per share, compared to a net loss of $84 million or $0.37 per share for the quarter ended June 30, 2021.

Agenus reported a revenue of $26 million for the quarter ended March 31, 2022, an increase of $14 million compared to the same quarter in 2021. The net loss for the quarter was $51 million, with per share losses of $0.19. The company ended the quarter with $263 million in cash and short-term investments.

Agenus reported a net income of $177 million, or $0.76 per share basic and $0.72 per share diluted, and ended the quarter with $262 million in cash and short-term investments. The company also highlighted clinical responses achieved with AGEN1181, the launch of MiNK Therapeutics' IPO, and the launch of its adjuvant business, SaponiQx.

Agenus reported a net loss of $84 million, or $0.37 per share, for the second quarter of 2021. The company's cash balance was $74 million at the end of the quarter, compared to $100 million at the end of 2020. Subsequent to the quarter end, Agenus received $200 million related to their BMS partnership.

Agenus reported a net loss of $54 million, or $0.27 per share, for the quarter ended March 31, 2021. The company ended the quarter with a cash balance of $119 million. Revenue for the quarter was $12 million.

Agenus reported a net loss for the fourth quarter of 2020, and the initiation of their rolling BLA filing for balstilimab monotherapy.

Agenus reported a net loss of $52 million, or $0.28 per share, for the third quarter of 2020. The company's cash balance at the end of the quarter was $114 million.

Agenus reported a net loss of $48 million, or $0.28 per share, for the second quarter of 2020. The company's cash balance at the end of the quarter was $79 million. Agenus recognized revenue of $26.945 million for the quarter.